First Ascent Biomedical’s core product is a functional precision medicine platform that integrates drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping to test hundreds of FDA-approved drugs against a patient’s unique cancer profile. The platform generates a personalized, actionable treatment plan for a patient’s physician in an average of 10 days. Company-reported results show patients treated with platform-guided decisions demonstrated an 83% greater benefit than those treated with standard-of-care physician choice. The technology was developed by co-founders Dr. Noah Berlow (CTO) and Dr. Diana Azzam (scientific advisor). The company says it will use the new capital to expand operations and open its first commercial lab in Florida, with an emphasis on making personalized care accessible to underserved communities. Leadership statements highlight the funding as a step toward scaling the technology and improving patient outcomes.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2025